Clinical Trial Update: An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand [Phase 1]

View source ↗

Summary

This is a Phase 1 open-label PET imaging study to assess GSK618334 in healthy male volunteers using 11C-PHNO as the PET ligand. The trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Substance Dependence

Drugs mentioned

• GSK618334

Snippet

Sponsor: GlaxoSmithKline | Conditions: Substance Dependence | Phase 1 | Status: COMPLETED